TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03941262

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: Patient-specific ex vivo expanded autologous natural killer cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: Patient-specific ex vivo expanded autologous natural killer cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: Patient-specific ex vivo expanded autologous natural killer cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: Patient-specific ex vivo expanded autologous natural killer cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: Patient-specific ex vivo expanded autologous natural killer cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death-ligand 1 (PD-L1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death receptor-1 (PD-1).
Study: NCT03073304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid based prime solution
Description: Crystalloid based prime solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythrocyte based prime solution
Description: Erythrocyte based prime solution
Study: NCT02636036

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: enadenotucirev

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Study: NCT00666575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 500 mg oral capsule 30 minutes prior to bedtime for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo oral capsule 30 minutes prior to bedtime for 28 days
Study: NCT02719366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A Extended Range test lens
Description: contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A Extended Range test lens
Description: contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A control lens
Description: contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A control lens
Description: contact lenses
Study: NCT02226783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722 salt tablet
Description: AZD1722 will be administered as 14 mg (salt tablet). tablet for oral use. Subjects will receive a 14 mg tablet in the morning and evening on Days 1 to 4 (Period 1), Days 7 to 10 (Period 2), and Days 13 to 16 (Period 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722 salt tablet
Description: AZD1722 will be administered as 14 mg (salt tablet). tablet for oral use. Subjects will receive a 14 mg tablet in the morning and evening on Days 1 to 4 (Period 1), Days 7 to 10 (Period 2), and Days 13 to 16 (Period 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722 salt tablet
Description: AZD1722 will be administered as 14 mg (salt tablet). tablet for oral use. Subjects will receive a 14 mg tablet in the morning and evening on Days 1 to 4 (Period 1), Days 7 to 10 (Period 2), and Days 13 to 16 (Period 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722 free base tablet
Description: AZD1722 will be given as four 14 mg free-base tablets (56mg) in the morning and evening on Days 1 to 4 (Period 1) and Days 10 to 13 (Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722 free base tablet
Description: AZD1722 will be given as four 14 mg free-base tablets (56mg) in the morning and evening on Days 1 to 4 (Period 1) and Days 10 to 13 (Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722 free base tablet + Omeprazole
Description: AZD1722 free base tablet administered 5 to 10 minutes before intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722
Study: NCT02923622

Intervention type: OTHER
Intervention: Traditional Chinese medicine herbals
Description: TCM herbal treatment based on TCM syndrome differentiation，without any anti tumor therapy in Western Medicine

Intervention type: OTHER
Intervention: Integrated traditional Chinese and Western medicine
Description: TCM herbal treatment combine with anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)

Intervention type: OTHER
Intervention: Western medicine
Description: Anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
Study: NCT03139253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: amoxicillin 1000 mg bid. for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: amoxicillin 1000 mg bid. for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: amoxicillin 1000 mg bid. for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: amoxicillin 1000 mg bid. for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: amoxicillin 1000 mg bid. for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Description: clarithromycin 500 mg bid. for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tinidazole
Description: tinidazole 500 mg bid. for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofloxacin
Description: levofloxacin 500 mg qd. for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furazolidone
Description: furazolidone 100 mg bid. for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetracycline
Description: tetracycline 750 mg bid. for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 5 mg bid. for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 5 mg bid. for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 5 mg bid. for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 5 mg bid. for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 5 mg bid. for 14 days.
Study: NCT02864914

Intervention type: DRUG
Intervention: Empagliflozin
Description: drug

Intervention type: DRUG
Intervention: DPP-4 inhibitors
Description: drug
Study: NCT01340170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed TX
Description: OsseoSpeed TX dental implants, 6-17 mm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OsseoSpeed TX
Description: OsseoSpeed TX dental implants, 6-17 mm
Study: NCT01356888

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention (Abbott Laboratories - Xience Prime DES)
Description: Stenting

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (Orsiro DES)
Description: stenting
Study: NCT04296682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar Ridge Preservation With Gingival Graft
Description: Closure of the alveolus with the placement of a free gingival tissue graft removed from the individual palate.
Study: NCT04595578

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebellar repetitive transcranial magnetic stimulation
Description: rTMS was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator with two Booster Modules (Magstim, Spring Gardens, Wales, UK) in accordance with safety recommendations. Stimulation was delivered to the cerebellum at 10 Hz with 90% of the mean resting motor threshold intensity for 5 seconds at 55 second intervals to deliver 1000 pulses in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cerebellar repetitive transcranial magnetic stimulation
Description: rTMS was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator with two Booster Modules (Magstim, Spring Gardens, Wales, UK) in accordance with safety recommendations. Stimulation was delivered to the cerebellum at 10 Hz with 90% of the mean resting motor threshold intensity for 5 seconds at 55 second intervals to deliver 1000 pulses in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
Study: NCT02313454

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intranasal Tear Neurostimulator
Description: Neurostimulation applied intranasally and extranasally.
Study: NCT02004340

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ear vagus nerve stimulator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ear vagus nerve stimulator
Study: NCT02984878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revanesse Ultra
Description: Nasolabial Fold correction
Study: NCT06094712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125134
Description: CORT125134 150-mg capsule
Study: NCT04729530

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dyson Pure Cool - Active Purifier
Description: Free standing air purifier

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dyson Pure Cool - Placebo purifier
Description: Placebo air purifier
Study: NCT02542449

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Globes®
Description: At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months Globes® and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months placebo and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
Study: NCT02313454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intranasal Tear Neurostimulator
Description: Neurostimulation applied intranasally and extranasally.
Study: NCT02551250

Intervention type: DEVICE
Intervention: annual noncontrast MRI
Description: liver MRI without contrast agents T2 weighted image, T1 in/out of phase, diffusion weighted images with b-values of 0, 500 mm2/s

Intervention type: DEVICE
Intervention: biannual ultrasonography
Description: liver ultrasonography for HCC screening performed by experienced sonologists
Study: NCT04325399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volitional help sheet
Study: NCT01578720

Intervention type: DRUG
Group type: OTHER
Intervention: EYLEA (Aflibercept) intravitreal injection
Description: Intravitreal Injection once every 8 weeks with 3 initial monthly doses
Study: NCT04720833

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dried plum
Description: Dried plum

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium and vitamin D
Description: Calcium and vitamin D supplement
Study: NCT01742052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303-Low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303-Middle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303-High

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02191397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion is an extended-release plain creamy white colored tablet which contains bupropion hydrochloride equivalent to 150 mg of bupropion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion Matching Placebo
Description: Bupropion hydrochloride matching placebo tablets will be supplied to maintain blinding

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram is available as a Swedish orange capsule containing escitalopram oxalate equivalent to 10 mg of escitalopram.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram Matching Placebo
Description: Escitalopram oxalate matching placebo tablets will be supplied to maintain blinding
Study: NCT02628067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: intravenous infusion
Study: NCT00890097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-8309B Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-8309B Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-8309B Vehicle
Description: Inactive ingredients used as placebo comparator
Study: NCT02608346

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Patients will have a blood draw at each visit to the hospital,~* with a maximum of 1 blood draw every 3 months, in absence of any abnormal clinical/radiological exam~* with a maximum of 1 blood draw every week, in case of abnormal clinical/radiological exam that requires further investigation
Study: NCT03948620

Intervention type: DRUG
Intervention: Macrolides
Description: Macrolide antibiotics, including erythromycin, clarithromycin and azithromycin. Prescriptions of macrolides will be identified using a drug code list based on the British National Formulary (chapter 5.1.5) and the date of the first prescription was used as the index date of exposure.

Intervention type: DRUG
Intervention: Penicillins
Description: The comparison group consists of children whose mother were prescribed penicillins during pregnancy. Prescriptions of penicillins will be identified using a drug code list based on the British National Formulary (chapter 5.1.1) and the date of the first prescription will be used as the index date of exposure.
Study: NCT02852005

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B vaccine
Description: 1×10\^8 TCID50 dose to be administered as a 1 mL intramuscular (IM) injection in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B vaccine
Description: 1×10\^8 TCID50 dose to be administered as a 1 mL intramuscular (IM) injection in the deltoid
Study: NCT04661020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells
Description: Each subject receive CD19 CAR T-cells by intravenous infusion
Study: NCT02330809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily extra water intake
Description: Amount of extra daily water intake to consume
Study: NCT02852005

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B vaccine
Description: 1×10\^8 TCID50 dose to be administered as a 1 mL intramuscular (IM) injection in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B vaccine
Description: 1×10\^8 TCID50 dose to be administered as a 1 mL intramuscular (IM) injection in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E vaccine
Description: 600 mcg/mL dose to be administered as a 1 mL IM injection in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E vaccine
Description: 600 mcg/mL dose to be administered as a 1 mL IM injection in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E vaccine
Description: 600 mcg/mL dose to be administered as a 1 mL IM injection in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride for Injection USP, 0.9% to be administered as a 1 mL IM injection in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride for Injection USP, 0.9% to be administered as a 1 mL IM injection in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride for Injection USP, 0.9% to be administered as a 1 mL IM injection in the deltoid
Study: NCT02239484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil + Tamsulosin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil + Tamsulosin
Study: NCT01947673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Study: NCT02796144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorcaserin
Description: Max dose of 10 mg BID
Study: NCT02239484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil + Tamsulosin
Study: NCT03702374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined antioxidant therapy
Description: It consists in a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1mg), vitamin C (L-ascorbic acid 180mg), vitamin E (DL-alpha tocopherol 30mg), zinc (zinc oxide 20mg), copper (copper sulfate 1mg), taken once a day for 12 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It consists in a capsule with 100mg of magnesium oxide.
Study: NCT01406054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuromuscular exercises
Description: neuromuscular exercises delivered as a pre-practice and pre-game warm-up including dynamic stretching, strengthening, and plyometrics.
Study: NCT03949114

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation
Description: Evaluate a weak debilitating phenotype screening on the patients before surgery;

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation
Description: Evaluate a weak debilitating phenotype screening on the patients before surgery;

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nursing care
Description: Traditional post-operative nursing care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: 1. Postoperative vital signs were stabilized for 2 hours and then assisted to turn over; 2 to 3 hours to change position, awake without swallowing dysfunction, to fluid diet; 6 hours later, raise the bed 15 to 30 °, eat a half-flow diet.~2. On the first day after surgery, raise the bed 45 °, row and position training; catheter clamping training; assessment of pain, preventive analgesia. Early rehabilitation training was performed for 60 minutes each time for 5 consecutive days.
Study: NCT03898609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: 3 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: 3 weeks
Study: NCT03272165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI1341
Description: Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI1341
Description: Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI1341
Description: Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI1341
Description: Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI1341
Description: Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI1341
Description: Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive IV infusion of placebo matched to MEDI1341.
Study: NCT03763266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 day low residue diet
Description: Patients are interviewed and instructed by a nurse prior the colonoscopy. They receive oral and written dietary information. In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
Study: NCT02796144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorcaserin
Description: Max dose of 10 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Max dose of 1,000 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebos will be administered for each drug.
Study: NCT01704872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ch14.18/CHO
Study: NCT02004990

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single cleansing procedure of 10% Povidone Iodine
Description: Single cleansing procedure of 10% Povidone Iodine prior to an in-office 5% Sodium Fluoride varnish application
Study: NCT03237845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: 75 mg tablet QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet to match rimegepant dose QD
Study: NCT01749735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Continuous mild transcranial direct current stimulation will be used while the participant plays video games using the Armeo Spring Robot to support the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.